Republican leaders say “step-by-step” process could take several years
Report predicts loss of $400 billion in hospital revenues as people lose coverage
Prescription device provides insulin dosing recommendations
New ovarian cancer indication joins several previous cancer approvals
Open letter expresses liberal concerns
Physicians prefer newer, more-costly drugs over generics
Second-line treatment extends survival by 5.7 months compared with platinum-pemetrexed
Treatment tops sitagliptin, exenatide, insulin glargine, and placebo in clinical trials

P&T December 2016
Table of Contents


A final rule from the Centers for Medicare and Medicaid Services has added pharmacy requirements for long-term-care facilities that put more responsibility on pharmacists but don’t address conflict-of-interest concerns.
Pharmacovigilance Forum
Rituximab can cause late-onset neutropenia that may result in serious life-threatening complications. The author describes the pathophysiology, incidence, and management of this adverse reaction and presents two case histories.
The authors review the evidence behind the use of thrombolytic therapy in patients with massive or submassive pulmonary embolism. Concurrent heparin therapy and the management of bleeding episodes are also discussed.
Short on funds and with no therapeutics or vaccines in sight, U.S. health officials are scrambling to prepare for a protracted fight with Zika virus and the mosquitoes that carry it. In this article, the author focuses on the arrival of Zika in the U.S.
Meeting Highlights
We review several key sessions from the European Society for Medical Oncology’s annual congress, including those on emerging immunotherapies for melanoma and non–small-cell lung cancer and on treatments for renal, ovarian, and breast cancer.
Season’s Greetings


Prescription: Washington
Medicare names plans for Part D MTM demo
Approvals, new indications, regulatory activities, and more
Lisinopril oral solution (Qbrelis) for the treatment of hypertension, heart failure, and acute myocardial infarction; etanercept-szzs (Erelzi) for multiple autoimmune disorders; and lumacaftor/ivacaftor (Orkambi) for cystic fibrosis
Drug Forecast
Daclatasvir (Daklinza) for chronic hepatitis C infection


How a Texas ACO Corralled Diabetes

Jose F. Peña, MD, head of the Rio Grande Valley ACO, describes impressive results for the organization’s comprehensive program to improve diabetes care and lower related Medicare costs in one of the nation’s poorest areas.

American Diabetes Association 76th Scientific Sessions, June 2016